Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting

NCT05549505 is registered in ClinicalTrials.gov with Arvinas Inc. as lead sponsor.

NCT NCT05549505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting
Lead sponsor
Arvinas Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2023
Completion date
July 25, 2024
Enrollment
152 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer